RSV help please

[nscr24x17x3]

Has anyone's baby ever had RSV? I just found out that the baby has it and am so confused with it. she has been on antibiotics for 4 days already because of an ear infection. she is now on a nebulizer and running a fever. One dr is telling me it isn't contagious and another is telling me it is? does anyone know about this? thank you in advance.

Faith

[PaulDaniel]

Luckily no, he got synagis the first two years, I am worried this year though. I have heard it is contagious with mucus dropelts, but not sure. Hope your LO gets better and here is a bump.

[nscr24x17x3]

Ruthie got the synagis shots last year but the insurance wouldn't pay for it this year. which i think is totally rediculous. so now she has it and I am so confused and don't understand any of it.

[PaulDaniel]

We faught with the insurance company the first two years, last year they were not going to give it to him until he ended up in childrens for 6 days with double pnemonia and bhroncialitis. Then they approved it really quick!!

Quoting nscr24x17x3:

Ruthie got the synagis shots last year but the insurance wouldn't pay for it this year. which i think is totally rediculous. so now she has it and I am so confused and don't understand any of it.

[nscr24x17x3]

I am going to call them tomorrow about it. I think that they need to give it to her. I don't know how much sickness her little body can handle. she is 9 1/2 months old and weighs almost 15lbs. plus with all the hospital stays she has had I don't know how they don't give it to her.

[fgrsk8queen]

This is some info if got from a website that may help answer some of your questions.. I also have had a preemie with RSV and almost lost him, he was is ICU on a ventelator for 3 mos before he was well enough to breath on his own. But my son was born with heart and lung disease, he has been on oxygen since birth, so this made it that much more serious in his case.

For otherwise healthy children, RSV usually amounts to little more than a cold. However, for preemies and other at-risk infants, the health consequences can be much more serious. In the US, approximately 125,000 children are hospitalized each year with serious RSV disease and sadly, some of these children die.

RSV spreads easily from person to person via respiratory secretions. The chance of spreading the virus within a family is very high. Many times school-aged children introduce the virus into the family. Despite strict infection control procedures, hospital nursery units, day care centers and other similar institutions are also at high-risk for RSV outbreaks.

[fgrsk8queen]

Quoting nscr24x17x3:

I am going to call them tomorrow about it. I think that they need to give it to her. I don't know how much sickness her little body can handle. she is 9 1/2 months old and weighs almost 15lbs. plus with all the hospital stays she has had I don't know how they don't give it to her.

They WILL approve it but you must stay on them, even if it takes a phone call every day and appeal everytime they deny the shot. your pediatrition should also be calling them regularly and explain WHY this is crutial for your daughter to have ASAP.. This is a matter of life or death to any preemie.

[asiamommi]

RSV, like any virus, is contagious. Keep up the nebs and keep her hydrated. Do you have a cool mist humidifier you can run in her room?

My former 36 weeker DS had RSV @ 18 months. He was hospitalized and now has asthma. If you can, fight for the Synagis! Here is The American Academy of Pediatrics new Synagis guidlines:

Eligibility criteria for prophylaxis of high-risk infants, young children

Infants with chronic lung disease of prematurity

No change is recommended for consideration of palivizumab prophylaxis for infants and children younger than 24 months of age who receive medical therapy (supplemental oxygen, bronchodilator, diuretic or chronic corticosteroid therapy)within six months before the start of the RSV season (a maximum of five monthly doses).

Infants born before 32 weeks’ gestation (31 weeks, 6 days or less)

No change is recommended for consideration of prophylaxis for infants born at or before 28 weeks’ gestationwho may benefit from prophylaxis during the RSV season, whenever that occurs during the first 12 months of life. Infants born at 29 to 32 weeks of gestation may benefit from prophylaxis up to 6 months of age (a maximum of five monthly doses).

Infants born at 32 weeks’ to less than 35 weeks’ gestation (32 weeks, 0 days through 34 weeks, 6 days)

A change has been made in the recommendation for infants in this category so that these infants receive a maximum of three doses. Available data do not enable definition of a subgroup of infants in this gestational age group at risk of prolonged hospitalization or admission to the intensive care unit. Therefore, recommendations have been modified to reduce the risk of RSV hospitalization during the period of greatest risk (the first 3 months of life) among infants with consistently identified risk factors for hospitalization.

Palivizumab prophylaxis should be limited to infants in this age group who are at greatest risk of hospitalization due to RSV, namely infants younger than 3 months of age at the start of the RSV season or born during the RSV season and who are likely to have an increased risk of exposure to RSV. Epidemiologic data suggest that RSV infection is more likely to occur and more likely to lead to hospitalization for infants in this gestational age group when either of the following two risk factors is present: infant attends child care or infant has a sibling younger than 5 years of age.

Prophylaxis may be considered for infants from 32 through less than 35 weeks’ gestation (32 weeks, 0 days through 34 weeks, 6 days) who are born less than three months before the onset or during the RSV season and forwhom at least one of the two risk factors is present. Infants in this gestational age category should receive prophylaxis only until they reach 3 months of age and should receive a maximum of three monthly doses;many will receive only one or two doses before they reach 3months of age. Once an infant is older than 90 days of age, the risk of hospitalization attributable to RSV lower respiratory tract disease is reduced. Administration of palivizumab is not recommended for these infants after they reach 90 days of age.